The purpose if this interventional First in Human study is to assess the Safety and Performance of the ALVIV System laser based treatment in patients diagnosed with Fecal Incontinence.

Eligible patients will go through screening assessments, followed by a series of 4-6 treatments with 3 weeks apart. Last follow up visit to the study will occur 3 weeks after last treatment day.

Participants will be asked to maintain a diary of their fecal incontinence episodes, and complete quality of life and satisfaction questionnaires throughout the study.

Inclusion Criteria:

• Onset of symptoms for uncontrolled passage of fecal material for at least 6 months prior to enrollment.
• At least 2-4 staining, solid or liquid FI episodes in the 4 weeks prior to enrollment
• Documented normal colonoscopy in the last 3 years
• Normal sigmoidoscopy as part of screening
• Signed consent

Exclusion Criteria:

• Pregnant or breastfeeding women
• Rectal prolapse grade ≥ III
• Hemorrhoids Grade ≥ II.
• Obstetrical injuries including third- and fourth-degree tears in the anal sphincter within the past 6 months
• Internal anal sphincter separation >270 degrees on Transrectal Ultrasound (TRUS).
• Congenital malformation of anus or rectum
• History of pelvic surgery in the past 6 months.
• inflammatory bowel disease.
• Presence of Intestinal stoma
• History of pelvic radiation within the previous 12 months or presence of active radiation proctitis.
• Presence of existing implant in the anal or rectal region.
• Active anal or rectal conditions in the last 6 months
• Abnormal blood coagulation
• Patients currently receiving immunotherapy or chemotherapy.

The sponsor does not plan to make individual participant data available to other researchers. The sponsor may consider sharing de-identified individual participant data upon reasonable request and subject to data use agreements.